Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation

Sagar Shelake, Don Eslin, Robert M. Sutphin, Umesh Tanaji Sankpal, Anmol Wadwani, Laura E. Kenyon, Leslie Tabor-Simecka, Paul Bowman, Jamboor K. Vishwanatha, Riyaz Mahammad Basha

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Chemotherapeutic regimens used for the treatment of Neuroblastoma (NB) cause long-term side effects in pediatric patients. NB arises in immature sympathetic nerve cells and primarily affects infants and children. A high rate of relapse in high-risk neuroblastoma (HRNB) necessitates the development of alternative strategies for effective treatment. This study investigated the efficacy of a small molecule, tolfenamic acid (TA), for enhancing the anti-proliferative effect of 13 cis-retinoic acid (RA) in HRNB cell lines. LA1-55n and SH-SY5Y cells were treated with TA (30. μM) or RA (20. μM) or both (optimized doses, derived from dose curves) for 48. h and tested the effect on cell viability, apoptosis and selected molecular markers (Sp1, survivin, AKT and ERK1/2). Cell viability and caspase activity were measured using the CellTiter-Glo and Caspase-Glo kits. The apoptotic cell population was determined by flow cytometry with Annexin-V staining. The expression of Sp1, survivin, AKT, ERK1/2 and c-PARP was evaluated by Western blots. The combination therapy of TA and RA resulted in significant inhibition of cell viability (. p<. 0.0001) when compared to individual agents. The anti-proliferative effect is accompanied by a decrease in Sp1 and survivin expression and an increase in apoptotic markers, Annexin-V positive cells, caspase 3/7 activity and c-PARP levels. Notably, TA. +. RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades. This study demonstrates that the TA mediated inhibition of Sp1 in combination with RA provides a novel therapeutic strategy for the effective treatment of HRNB in children.

Original languageEnglish
Pages (from-to)92-99
Number of pages8
JournalInternational Journal of Developmental Neuroscience
Volume46
DOIs
StatePublished - 1 Nov 2015

Fingerprint

Isotretinoin
Neuroblastoma
Tretinoin
Cell Proliferation
Apoptosis
Cell Survival
Annexin A5
Caspases
Caspase 7
Therapeutics
Caspase 3
Flow Cytometry
Down-Regulation
Western Blotting
tolfenamic acid
Pediatrics
Staining and Labeling
Neurons
Recurrence
Cell Line

Keywords

  • Chemotherapy
  • Infants
  • Neuroblastoma
  • Retinoic acid
  • Sympathetic nervous system
  • Tolfenamic acid

Cite this

@article{a818db9d06864ae28d3b87304eab129f,
title = "Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation",
abstract = "Chemotherapeutic regimens used for the treatment of Neuroblastoma (NB) cause long-term side effects in pediatric patients. NB arises in immature sympathetic nerve cells and primarily affects infants and children. A high rate of relapse in high-risk neuroblastoma (HRNB) necessitates the development of alternative strategies for effective treatment. This study investigated the efficacy of a small molecule, tolfenamic acid (TA), for enhancing the anti-proliferative effect of 13 cis-retinoic acid (RA) in HRNB cell lines. LA1-55n and SH-SY5Y cells were treated with TA (30. μM) or RA (20. μM) or both (optimized doses, derived from dose curves) for 48. h and tested the effect on cell viability, apoptosis and selected molecular markers (Sp1, survivin, AKT and ERK1/2). Cell viability and caspase activity were measured using the CellTiter-Glo and Caspase-Glo kits. The apoptotic cell population was determined by flow cytometry with Annexin-V staining. The expression of Sp1, survivin, AKT, ERK1/2 and c-PARP was evaluated by Western blots. The combination therapy of TA and RA resulted in significant inhibition of cell viability (. p<. 0.0001) when compared to individual agents. The anti-proliferative effect is accompanied by a decrease in Sp1 and survivin expression and an increase in apoptotic markers, Annexin-V positive cells, caspase 3/7 activity and c-PARP levels. Notably, TA. +. RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades. This study demonstrates that the TA mediated inhibition of Sp1 in combination with RA provides a novel therapeutic strategy for the effective treatment of HRNB in children.",
keywords = "Chemotherapy, Infants, Neuroblastoma, Retinoic acid, Sympathetic nervous system, Tolfenamic acid",
author = "Sagar Shelake and Don Eslin and Sutphin, {Robert M.} and Sankpal, {Umesh Tanaji} and Anmol Wadwani and Kenyon, {Laura E.} and Leslie Tabor-Simecka and Paul Bowman and Vishwanatha, {Jamboor K.} and Basha, {Riyaz Mahammad}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.ijdevneu.2015.07.012",
language = "English",
volume = "46",
pages = "92--99",
journal = "International Journal of Developmental Neuroscience",
issn = "0736-5748",
publisher = "Elsevier Ltd",

}

Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation. / Shelake, Sagar; Eslin, Don; Sutphin, Robert M.; Sankpal, Umesh Tanaji; Wadwani, Anmol; Kenyon, Laura E.; Tabor-Simecka, Leslie; Bowman, Paul; Vishwanatha, Jamboor K.; Basha, Riyaz Mahammad.

In: International Journal of Developmental Neuroscience, Vol. 46, 01.11.2015, p. 92-99.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Combination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation

AU - Shelake, Sagar

AU - Eslin, Don

AU - Sutphin, Robert M.

AU - Sankpal, Umesh Tanaji

AU - Wadwani, Anmol

AU - Kenyon, Laura E.

AU - Tabor-Simecka, Leslie

AU - Bowman, Paul

AU - Vishwanatha, Jamboor K.

AU - Basha, Riyaz Mahammad

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Chemotherapeutic regimens used for the treatment of Neuroblastoma (NB) cause long-term side effects in pediatric patients. NB arises in immature sympathetic nerve cells and primarily affects infants and children. A high rate of relapse in high-risk neuroblastoma (HRNB) necessitates the development of alternative strategies for effective treatment. This study investigated the efficacy of a small molecule, tolfenamic acid (TA), for enhancing the anti-proliferative effect of 13 cis-retinoic acid (RA) in HRNB cell lines. LA1-55n and SH-SY5Y cells were treated with TA (30. μM) or RA (20. μM) or both (optimized doses, derived from dose curves) for 48. h and tested the effect on cell viability, apoptosis and selected molecular markers (Sp1, survivin, AKT and ERK1/2). Cell viability and caspase activity were measured using the CellTiter-Glo and Caspase-Glo kits. The apoptotic cell population was determined by flow cytometry with Annexin-V staining. The expression of Sp1, survivin, AKT, ERK1/2 and c-PARP was evaluated by Western blots. The combination therapy of TA and RA resulted in significant inhibition of cell viability (. p<. 0.0001) when compared to individual agents. The anti-proliferative effect is accompanied by a decrease in Sp1 and survivin expression and an increase in apoptotic markers, Annexin-V positive cells, caspase 3/7 activity and c-PARP levels. Notably, TA. +. RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades. This study demonstrates that the TA mediated inhibition of Sp1 in combination with RA provides a novel therapeutic strategy for the effective treatment of HRNB in children.

AB - Chemotherapeutic regimens used for the treatment of Neuroblastoma (NB) cause long-term side effects in pediatric patients. NB arises in immature sympathetic nerve cells and primarily affects infants and children. A high rate of relapse in high-risk neuroblastoma (HRNB) necessitates the development of alternative strategies for effective treatment. This study investigated the efficacy of a small molecule, tolfenamic acid (TA), for enhancing the anti-proliferative effect of 13 cis-retinoic acid (RA) in HRNB cell lines. LA1-55n and SH-SY5Y cells were treated with TA (30. μM) or RA (20. μM) or both (optimized doses, derived from dose curves) for 48. h and tested the effect on cell viability, apoptosis and selected molecular markers (Sp1, survivin, AKT and ERK1/2). Cell viability and caspase activity were measured using the CellTiter-Glo and Caspase-Glo kits. The apoptotic cell population was determined by flow cytometry with Annexin-V staining. The expression of Sp1, survivin, AKT, ERK1/2 and c-PARP was evaluated by Western blots. The combination therapy of TA and RA resulted in significant inhibition of cell viability (. p<. 0.0001) when compared to individual agents. The anti-proliferative effect is accompanied by a decrease in Sp1 and survivin expression and an increase in apoptotic markers, Annexin-V positive cells, caspase 3/7 activity and c-PARP levels. Notably, TA. +. RA combination also caused down regulation of AKT and ERK1/2 suggesting a distinct impact on survival and proliferation pathways via signaling cascades. This study demonstrates that the TA mediated inhibition of Sp1 in combination with RA provides a novel therapeutic strategy for the effective treatment of HRNB in children.

KW - Chemotherapy

KW - Infants

KW - Neuroblastoma

KW - Retinoic acid

KW - Sympathetic nervous system

KW - Tolfenamic acid

UR - http://www.scopus.com/inward/record.url?scp=84940764954&partnerID=8YFLogxK

U2 - 10.1016/j.ijdevneu.2015.07.012

DO - 10.1016/j.ijdevneu.2015.07.012

M3 - Article

VL - 46

SP - 92

EP - 99

JO - International Journal of Developmental Neuroscience

JF - International Journal of Developmental Neuroscience

SN - 0736-5748

ER -